Health
Commented by André Will-Laudien on July 30th, 2025 | 07:00 CEST
Trump's Tariffs & Takeovers! BioNTech, PanGenomic Health, Pfizer, and Valneva Targeted by Speculators
The US-EU tariff agreement has now been finalized. Many sectors of the European economy will now face additional burdens and margin cuts. The biotech and pharmaceutical industries have been spared, as medicines and active pharmaceutical ingredients are among the few product groups that are traditionally traded duty-free in transatlantic trade. This is due to international agreements, such as the WTO Pharmaceutical Agreement, which both the EU and the US have signed. Clinical trial drugs, active ingredient imports, and vaccines are also mostly exempt from tariffs. Valneva is currently making headlines with its chikungunya vaccine, BioNTech and Pfizer are continuing to sell COVID-19 vaccines on a small scale, and PanGenomic is surprising everyone with a new AI-powered health platform. A lot is going on in the sector – who are the big earners?
Read
Commented by Nico Popp on July 24th, 2025 | 07:10 CEST
No high-tech without tungsten – This bottleneck brings returns: Almonty, Siemens Healthineers, Intel
Tungsten is known as a defense metal due to its hardness and heat resistance. But it is also one of the invisible drivers of the high-tech industry. Using examples from medical technology and chip manufacturing, we explain why tungsten is rightly considered a key element in the future of raw material supply. We also venture a long-term outlook on the potential of tungsten producer Almonty Industries' stock.
Read
Commented by Nico Popp on July 21st, 2025 | 07:15 CEST
A turning point in German healthcare! Are we moving closer to the US model? PanGenomic Health, Bayer, and Nestlé
Are US-style conditions soon coming to Germany? Health economist Jürgen Wasem is calling for greater patient cost-sharing. Certain medications could be made available over the counter, allowing patients to access them more easily at their own expense. This could help reduce costs. This form of self-medication has long been common in the US, where people with certain ailments naturally turn to over-the-counter preparations or potent health foods. How can investors benefit from this trend? We present the shares of Bayer, Nestlé, and PanGenomic Health!
Read
Commented by Fabian Lorenz on July 16th, 2025 | 07:25 CEST
WINNING STOCKS for the second half of the year!? Rheinmetall, Bayer, and Hotstock PanGenomic Health
Hard to believe: Bayer shares are among the winners in 2025. And even the news flow is positive. Does the Leverkusen-based company even have a new blockbuster in the pipeline? What do analysts say? PanGenomic Health shares could be among the stars of the second half of the year. With a new health app, the Company is entering a billion-dollar market in the US and benefiting from the Trump administration. If it succeeds in securing market share, the stock should have plenty of upside potential. Analysts believe that the air is getting thinner for Rheinmetall shares. However, it is likely only a matter of time before the EUR 2,000 mark is broken.
Read
Commented by Armin Schulz on July 16th, 2025 | 07:10 CEST
Novo Nordisk, BioNxt Solutions, BioNTech – How to heal your portfolio with the 2025 healthcare revolution
The global healthcare system is facing a turning point in 2025. Climate change, chronic diseases, and the scars left by pandemics are challenging existing systems, while digitalization and AI are rapidly advancing new therapies. Governments are investing billions in modern healthcare infrastructure, but debates about data protection and scheduling doctor's appointments are escalating. While the WHO warns of stagnation, groundbreaking alliances between research and industry are emerging. This is precisely where Novo Nordisk, BioNxt Solutions, and BioNTech come in with visionary technologies that not only heal but also open up opportunities for investors.
Read
Commented by Armin Schulz on June 24th, 2025 | 07:30 CEST
Portfolio Doubler with Artificial Intelligence: Novo Nordisk, PanGenomic Health, and Pfizer Ignite the Profit Growth in 2025
According to BlackRock Health Sciences, the global healthcare sector is poised for an unprecedented boom in 2025. After years of volatility driven by the pandemic, the industry is now expected to achieve its highest profit growth in almost two decades - and across the board, not just among pandemic-driven outliers. Digital revolutions such as AI-assisted drug development and telemedicine are accelerating change and creating radically new business models. Those who understand the architects of this transformation will recognize the growth drivers of tomorrow. With this in mind, we take a closer look at three key companies: Novo Nordisk, PanGenomic Health, and Pfizer.
Read
Commented by Nico Popp on June 10th, 2025 | 07:20 CEST
Future market – Worth about USD 50 billion: Illumina, Moderna, PanGenomic Health
Medicine is becoming personal. The era of one-size-fits-all drugs is coming to an end. Experts at BCC Research predict that the market for personalized medicine will grow from USD 54.2 billion in 2023 to USD 100.5 billion by 2028. That represents an annual growth rate of 13.2%. Other analysis firms, such as Grand View Research and Market Research Intellect, confirm this promising outlook for investors. All the more reason to take a closer look at Illumina, Moderna, and PanGenomic Health and explore the opportunities they present for investors.
Read
Commented by Armin Schulz on June 6th, 2025 | 07:00 CEST
The US healthcare revolution: How are Bayer, PanGenomic Health, and Pfizer positioned?
The US healthcare system is undergoing unprecedented change under Secretary Robert F. Kennedy Jr. Pharmaceutical giants are groaning under drastic price controls and regulatory upheaval, while digital healthcare pioneers are sensing unprecedented opportunities. This systemic shock is tearing down old power structures and catapulting agile players to the forefront – an explosive interplay of risk and opportunity. Those who understand the new rules of the game will discover lucrative prospects amid the chaos. Today, we take a look at Bayer, PanGenomic Health, and Pfizer to see who stands to benefit.
Read
Commented by Fabian Lorenz on June 3rd, 2025 | 07:10 CEST
SHOCK for RENK, "BUY" rating for Novo Nordisk, and PanGenomic Health follows in the footsteps of Hims & Hers
Shock for RENK & Co.! Yesterday afternoon, news broke that the EU plans to tap into the billions in profits made by defense companies. After all, these companies are facing a golden age. The shares ended their record run yesterday. The alternative medicine and dietary supplements sector is currently experiencing a boom in the US. PanGenomic Health wants a piece of that multi-billion-dollar market. The newcomer is launching an AI-based app offering recommendations, a marketplace, and diagnostics. The rollout will begin this summer. Anyone who missed out on the 800% gains at Hims & Hers should take a look at this newcomer. Novo Nordisk is a core investment in the pharmaceutical sector. However, expectations for the blockbuster drug Ozempic were likely set too high. After the stock's crash, things are now looking better again.
Read
Commented by Nico Popp on May 28th, 2025 | 06:55 CEST
Smart innovations for strong returns: BioNTech, BioNxt Solutions, and Siemens Healthineers
For a new drug to hit the market, it has to outperform existing alternatives – so innovation is key for biotech companies. In medical technology, too, innovations must first and foremost benefit patients. However, research and development are expensive. We analyze how BioNTech, BioNxt Solutions, and Siemens Healthineers are driving innovation and what that means for investors.
Read